[Featured Stock] Mico BioMed Rises on WHO's Decision to Maintain Mpox International Public Health Emergency Status

Mico BioMed is showing strong performance. This is interpreted as being influenced by the World Health Organization (WHO) maintaining the highest level of alert for Mpox (formerly known as monkeypox).

As of 9:32 AM on the 25th, Mico BioMed is trading at 1,722 KRW, up 27.46% compared to the previous day.

The WHO committee, at a meeting held in Geneva on the 22nd, assessed that Mpox, which is spreading mainly in Africa, still qualifies as a Public Health Emergency of International Concern (PHEIC). WHO explained, "This decision is based on the increase in infection cases, geographical spread, and the overall need for a coordinated response."

According to the Africa Centers for Disease Control and Prevention (CDC), as of the 13th, suspected Mpox cases reported in Africa this year reached 53,903. Among these, 11,147 cases were confirmed, and 1,109 people died.

Among the 55 member countries of the African Union (AU), 19 countries have reported Mpox outbreaks, with most cases and deaths occurring in Central Africa, including the Democratic Republic of the Congo.

Mpox is an acute febrile rash illness caused by a viral infection. Since early this year, WHO declared a PHEIC in August after the spread of a new variant, Clade 1b, which has a high fatality rate and rapid transmission, mainly in Africa.

Meanwhile, Mico BioMed is known as the first company in Korea to possess in vitro diagnostic technology capable of detecting Mpox.